Werewolf Therapeutics Announces 2024 Annual Meeting of Stockholders
Ticker: HOWL · Form: DEF 14A · Filed: Apr 12, 2024 · CIK: 1785530
| Field | Detail |
|---|---|
| Company | Werewolf Therapeutics, Inc. (HOWL) |
| Form Type | DEF 14A |
| Filed Date | Apr 12, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Stockholders, Director Election, Auditor Ratification
TL;DR
<b>Werewolf Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on May 24, 2024, to elect directors and ratify auditors.</b>
AI Summary
Werewolf Therapeutics, Inc. (HOWL) filed a Proxy Statement (DEF 14A) with the SEC on April 12, 2024. Annual meeting to be held virtually on May 24, 2024, at 9:00 a.m. ET. Stockholders of record as of April 1, 2024, are eligible to vote. Key agenda items include the election of three Class III directors. Ratification of Ernst & Young LLP as independent registered public accounting firm for FY2024. Meeting will be conducted exclusively online at www.virtualshareholdermeeting.com/HOWL2024.
Why It Matters
For investors and stakeholders tracking Werewolf Therapeutics, Inc., this filing contains several important signals. The virtual format is intended to increase stockholder attendance and participation globally. The meeting will address director elections and auditor ratification, crucial for corporate governance and financial oversight.
Risk Assessment
Risk Level: low — Werewolf Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the director nominees and the ratification of the auditor to make informed voting decisions.
Key Numbers
- May 24, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
- April 1, 2024 — Record Date (Stockholders must own shares as of this date to vote)
- 3 — Directors to be Elected (Number of Class III directors to be elected)
- 3-year term — Director Term Length (Term length for elected directors)
Key Players & Entities
- Werewolf Therapeutics, Inc. (company) — Registrant
- Ernst & Young LLP (company) — Independent registered public accounting firm
- May 24, 2024 (date) — Date of Annual Meeting
- April 1, 2024 (date) — Record date for voting eligibility
- 2027 (date) — Director term expiration
- December 31, 2024 (date) — Fiscal year end
FAQ
When did Werewolf Therapeutics, Inc. file this DEF 14A?
Werewolf Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 12, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Werewolf Therapeutics, Inc. (HOWL).
Where can I read the original DEF 14A filing from Werewolf Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Werewolf Therapeutics, Inc..
What are the key takeaways from Werewolf Therapeutics, Inc.'s DEF 14A?
Werewolf Therapeutics, Inc. filed this DEF 14A on April 12, 2024. Key takeaways: Annual meeting to be held virtually on May 24, 2024, at 9:00 a.m. ET.. Stockholders of record as of April 1, 2024, are eligible to vote.. Key agenda items include the election of three Class III directors..
Is Werewolf Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Werewolf Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Werewolf Therapeutics, Inc.'s DEF 14A?
Stockholders should review the director nominees and the ratification of the auditor to make informed voting decisions. The overall sentiment from this filing is neutral.
How does Werewolf Therapeutics, Inc. compare to its industry peers?
Werewolf Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.
Are there regulatory concerns for Werewolf Therapeutics, Inc.?
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, governing proxy solicitations.
Risk Factors
- Solicitation of Proxies [low — regulatory]: The company is soliciting proxies for its 2024 Annual Meeting of Stockholders, which requires adherence to SEC rules and regulations.
- Virtual Meeting Format [low — operational]: The exclusive virtual format may present challenges for some stockholders in attending or participating in the meeting.
Industry Context
Werewolf Therapeutics operates in the pharmaceutical preparations industry, focusing on developing novel therapeutics.
Regulatory Implications
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the biographical information and qualifications of the director nominees.
- Evaluate the independence and qualifications of Ernst & Young LLP as the proposed auditor.
- Understand the voting procedures and deadlines for the virtual Annual Meeting.
Key Dates
- 2024-05-24: 2024 Annual Meeting of Stockholders — Key date for voting and director elections.
- 2024-04-01: Record Date — Determines eligibility to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing, which is a standard proxy statement for an annual meeting and does not represent a change from previous filings of this type.
Filing Stats: 4,618 words · 18 min read · ~15 pages · Grade level 12.1 · Accepted 2024-04-12 07:16:19
Filing Documents
- ny20024347x1_def14a.htm (DEF 14A) — 483KB
- logo_werewolf.jpg (GRAPHIC) — 48KB
- sig_djhicklin.jpg (GRAPHIC) — 16KB
- ny20024347x1_pc01.jpg (GRAPHIC) — 579KB
- ny20024347x1_pc02.jpg (GRAPHIC) — 435KB
- 0001140361-24-019504.txt ( ) — 1969KB
From the Filing
DEF 14A 1 ny20024347x1_def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ ​ ​ Filed by a Party other than the Registrant   ☐ Check the appropriate box:   ☐ ​ ​ Preliminary Proxy Statement   ☐ ​ ​ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ ​ ​ Definitive Proxy Statement   ☐ ​ ​ Definitive Additional Materials   ☐ ​ ​ Soliciting Material under §240.14a-12 WEREWOLF THERAPEUTICS, INC. (Name of registrant as specified in its charter) (Name of person(s) filing proxy statement, if other than the registrant) Payment of Filing Fee (Check the appropriate box): ☒ ​ ​ No fee required   ☐ ​ ​ Fee paid previously with preliminary materials   ☐ ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 TABLE OF CONTENTS   200 Talcott Ave, 2nd Floor Watertown, Massachusetts 02472 NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held on May 24, 2024 Dear Stockholders: You are cordially invited to virtually attend the 2024 annual meeting of stockholders, or the Annual Meeting, of Werewolf Therapeutics, Inc. The Annual Meeting will be held via the Internet at a virtual web conference at www.virtualshareholdermeeting.com/HOWL2024 on Friday, May 24, 2024, at 9:00 a.m., Eastern time. Only stockholders who owned shares of our common stock at the close of business on April 1, 2024, can vote at the Annual Meeting or any adjournment thereof. At the Annual Meeting, the stockholders will consider and vote on the following matters: 1. Election of three Class III directors nominated by our board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders; 2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024; and 3. Transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof. As noted above, our Annual Meeting will be a “virtual meeting” of stockholders, which will be conducted exclusively via the Internet at a virtual web conference. There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. This means that you can attend the Annual Meeting online, vote your shares and submit questions during the online meeting. We believe that hosting a “virtual meeting” will enable greater stockholder attendance and participation from any location around the world. You can find more information, including the nominees for director, in the attached proxy statement for the Annual Meeting. The board of directors recommends that you vote “FOR” each of the Class III directors (Proposal 1) and “FOR” the ratification of the appointment of the proposed independent registered public accounting firm (Proposal 2) as outlined in the attached proxy statement. We are pleased to comply with the rules of the Securities and Exchange Commission that allow companies to distribute their proxy materials over the Internet under the “notice and access” approach. As a result, we are sending to our stockholders a Notice of Internet Availability of Proxy Materials, or the Notice of Availability, instead of a paper copy of this proxy statement and our annual report for the fiscal year ended December 31, 2023, or the 2023 Annual Report. We will mail the Notice of Availability on or about April 12, 2023, and the Notice of Availability contains instructions on how to access our proxy materials over the Internet. The Notice of Availability also contains instructions on how each of our stockholders can receive a paper copy of our proxy materials, including the proxy statement, our 2023 Annual Report, and a form of proxy card. Stockholders of record at the close of business on April 1, 2023, the record date for the Annual Meeting, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment or postponement thereof. Whether or not you expect to virtually attend the Annual Meeting online, please vote your shares to ensure your representation and the presence of a quorum at the Annual Meeting. A complete list of registered stockholders will be available at least ten days prior to the meeting for inspection at our offices at 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts 02472. This